SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great

MORE HEADLINES

» Markets | Economy | Companies

- Move Into High-Quality Stocks Could Move Market Higher

PHARMA'S MARKET VIDEO

» More

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

Pharma & Social Media 12 Nov 2009
The FDA is holding meetings into big pharma's possible use of social media to sell their products. CNBC's Mike Huckman has the details.

"Friending" Big Pharma

12 Nov 2009

Big pharma is embracing social media, but how much can or should a tightly regulated sector be able to say on Facebook or Twitter? CNBC's Mike Huckman takes a closer look.

SNY Out with H1N1 Test Results 11 Nov 2009
Sanofi Aventis confirms that kids 9 and under need not one but two H1N1 shots, with CNBC's Mike Huckman.
Making The Vaccine 06 Nov 2009
Inside the big push to get enough H1N1 vaccines, with CNBC's Mike Huckman.
Making the Flu Vaccine 06 Nov 2009
Wayne Pisano, CEO of Sanofi-Pasteur, discusses the making of the flu vaccine with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

May.24

3:16 PM ET

Thursday, 24 May 2007

Lipitor: Loser

Posted By:Mike Huckman

Topics:Medicine | Pharmaceuticals

Companies:Dr. Reddy's Laboratories Ltd | Teva Pharmaceutical Industries Limited | Pfizer Inc | Merck & Co Inc

Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.

Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"

He goes on to write, "Simvastatin Still on Course to Catch Lipitor" (the bold type is his emphasis). "... (Merck's) [MRK Loading... () ] Zocor and simvastatin now hold a 23.9% total prescription share. Lipitor, on the other hand, has declined from a 41.8% total prescription share last year to a 33.5% share now. Unless Pfizer [PFE Loading... () ] can significantly change Lipitor's trajectory it appears to be only a matter of time before simvastatin becomes the market leader in the cholesterol-lowering market."

You may recall that in its first-quarter earnings release, Pfizer said for the first time that Lipitor sales possibly could be down modestly this year. Nonetheless, it is still by far the world's top-selling drug. A bunch of companies, including Israel's Teva Pharmaceuticals [TEVA Loading... () ] and India's Dr. Reddy's Laboratories [RDY Loading... () ], make generic simvastatin.

Tooley's data are based on numbers from IMS Health (a company that monitors prescriptions) and AG Edwards estimates. AGE or one of its officers has a long position in PFE.